Friday, January 17, 2020 Daily Archives

Sarepta plans gene editing center; files DMD therapy for review

by

Genetic disease-focused firms need infrastructure says Sarepta, which shared plans for a gene editing center of excellence at the JP Morgan healthcare conference. The gene editing center will be in Durham, North Carolina according to CEO Douglas Ingram, who said investing in capacity and knowhow is key to Sarepta’s longevity. “If one is going to be an enduring genetic medicine company, we are going to need infrastructure,†he said, citing partnerships as an important part of the expansion. “We’re deepening…

January 17, 2020

WuXi Biologics adds Bayer drug product plant to growing network

by

WuXi Biologics has leased a drug product plant in Leverkusen, Germany from Bayer and is in negotiations to continue making hemophilia therapy Kovaltry for the Big Biopharma firm. The lease agreement – financials of which have not been divulged – gives Chinese contract development and manufacturing organization (CDMO) WuXi Biologics its first drug product facility outside of Europe. WuXi Biologics has been rampant in building up its manufacturing network, and while it has so far focused on constructing sites, the…

January 17, 2020

Merck pays Just-Evotec $15m for ‘J.POD’ manufacturing capacity

by

Merck & Co. has reserved capacity at Just-Evotec’s modular and biomanufacturing facility in Redmond, Washington, which is currently under construction. Months after German services firm Evotec acquired biologics development and manufacturing firm Just.Bio for $90 million (€81 million), plans were drawn up to construct a commercial-scale facility near Seattle in Washington state. While the plant is in the early stages of construction, Just-Evotec has confirmed Merck & Co. (known as MSD outside of North America) has reserved capacity at the…

January 17, 2020